herpes zoster ophthalmicus; This literature-study case was reported in a literature article and describes the occurrence of OPHTHALMIC HERPES ZOSTER (herpes zoster ophthalmicus) in a 49-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.      Concurrent medical conditions included Bipolar disorder, Schizophrenia and Hyperlipidemia.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced OPHTHALMIC HERPES ZOSTER (herpes zoster ophthalmicus) (seriousness criterion medically significant). At the time of the report, OPHTHALMIC HERPES ZOSTER (herpes zoster ophthalmicus) was resolving. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: 146/84 BP 146/84. On an unknown date, Body temperature: 100f Temp 100F. On an unknown date, Haemoglobin (13.5 g/dl-17.5 g/dl): 16.9 g/dl (normal) hemoglobin 16.9 g/dL. On an unknown date, Heart rate: 88 HR 88. On an unknown date, Physical examination: abnormal (abnormal) revealed grouped erythematous papules and vesicles on the right side of the forehead (i.e., V1 dermatome) and edema of the right upper eyelid. Based on the clinical examination, the diagnosis of HZO was made.. On an unknown date, Platelet count (150k-450k): 198k cells/microliter (normal) platelets 198K cells/microliter. On an unknown date, Respiratory rate: 20 RR 20. On an unknown date, White blood cell count (4,500-11,000): 6.70 cells/microliter White count 6.70 cells/microliter.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered OPHTHALMIC HERPES ZOSTER (herpes zoster ophthalmicus) to be possibly related.    Concomitant product use was not provided by the author.   Patient was healthy without any physical or emotional stressors. Patient has no history of shingles in the past  Patient  presented to the emergency room with worsening burning pain on the right side of the forehead and blurred vision.   He denied having any other complaints. He works as a caretaker and lives with his parents. Furthermore, he denied having any stressors at work or home.  Patient was started on systemic antiviral therapy with an improvement of his symptoms.  Author concluded that HZ post COVID-19 vaccine is beyond coincidence. Awareness must be created among physicians, as well as the general public by reporting any associations with the COVID-19 vaccine and HZ to CDC. Early recognition and antiviral usage can halt the progression of the disease and thus prevent debilitating complications. The fear of HZ should not inhibit individuals from receiving the COVID-19 vaccine. Further studies must be conducted to completely understand the pathophysiology and construct preventive measures.  This case concerns a 49-year-old, male subject with no relevant medical history, who experienced the unexpected event of ophthalmic herpes zoster. The event occurred 1 week after administration of the first dose. The rechallenge was not applicable as the event occurred after the first dose. The event was considered possibly related to the Moderna COVID-19 vaccine per the reporter's assessment. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event seriousness was assessed as medically significant since the patient is at risk of debilitating and life-threatening complications if not treated.   Most recent FOLLOW-UP information incorporated above includes: On 15-Sep-2021: Follow up received on 15-Sep-2021 has Email and does not contain any new information. On 17-Sep-2021: Follow up received on 17-Sep-2021 has Email and does not contain any new information.; Sender's Comments: This case concerns a 49-year-old, male subject with no relevant medical history, who experienced the unexpected event of ophthalmic herpes zoster. The event occurred 1 week after administration of the first dose. The rechallenge was not applicable as the event occurred after the first dose. The event was considered possibly related to the Moderna COVID-19 vaccine per the reporter's assessment. The benefit-risk relationship of mRNA-1273 is not affected by this report. Event seriousness was assessed as medically significant since the patient is at risk of debilitating and life-threatening complications if not treated.